AUG 19, 2015 12:52 PM PDT

Biomarkers to Diagnose Lung Cancer

WRITTEN BY: Ilene Schneider
Warnings about the dangers of smoking started in the 1960s, but lung cancer remains the second-most common cancer and the leading cause of death from cancer in the United States. Because patients are often diagnosed only when their disease is already at an advanced stage and hard to treat, researchers at the West Coast Metabolomics Center at UC Davis have attempted to identify biomarkers that could be the basis of early tests for lung cancer. The study was reported in Science Daily
Metabolomics catches cancer earlier. 
According to Oliver Fiehn, director of the metabolomics center and a professor of molecular and cellular biology at UC Davis, "Early diagnosis is the key to fighting lung cancer."
 
While lung cancer can be diagnosed early with regular low-dose computed tomography (CT) scans of people at risk, but they are both expensive and invasive. Fiehn, project scientist William Wikoff and their colleagues decided to look for biomarkers of developing lung cancer in blood from patients. Fiehn specializes in "metabolomics," which analyzes all of the biochemical products of metabolism in cells and tissues at the same time. The discipline, which is made possible by new technology and computing power, is opening up new ways to understand living processes.
 
The team looked at blood samples collected from people who developed the lung cancer, months or years before they were diagnosed. They were able to access samples stored from the CARET clinical trial, which ran from 1985 to 1996 and attempted to test whether doses of antioxidant vitamins could prevent cancer in heavy smokers and other people at high risk. While the trial failed, the collection of blood, serum and tissues and related data are maintained as the CARET Biorepository.
 
Using metabolomics, Wikoff and Fiehn discovered that one molecule, diacetylspermine, was almost doubled in serum collected from patients as many as six months before they were diagnosed with lung cancer, compared to healthy controls. They combined diacetylspermine with another previously identified biomarker, a protein called pro-surfactant protein B (pro-SFTPB), and tested for both markers in another set of sera collected from CARET patients months before they developed lung cancer.
 
Individually, the markers were about 70 percent predictive; in combination, they were 80 percent predictive. Thus, eight out of ten people with early-stage cancer could be correctly identified by the combined test. If this method were used, patients could then be referred for a low-dose CT scan to confirm the presence of cancer.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
FEB 10, 2021
Drug Discovery & Development
Black Men Respond Best to Immunotherapy for Prostate Cancer
FEB 10, 2021
Black Men Respond Best to Immunotherapy for Prostate Cancer
Researchers from Northwestern University have found that Black men and men of African ancestry respond better than men f ...
MAR 22, 2021
Cancer
Can we use our own bacteria to fight cancer?
MAR 22, 2021
Can we use our own bacteria to fight cancer?
New research highlighted recently in Nature explores the ways that bacteria in tumors could be targeted to trigger immun ...
APR 14, 2021
Cancer
Fighting back against medulloblastoma with naturally-occurring compound
APR 14, 2021
Fighting back against medulloblastoma with naturally-occurring compound
Renewed hope for young children with medulloblastoma comes in the form of a research paper published from the Queen Mary ...
APR 19, 2021
Cancer
Understanding why pacreatic cancer metastasizes
APR 19, 2021
Understanding why pacreatic cancer metastasizes
New research published in the journal Gastroenterology reports on the mechanisms of metastatic pancreatic cancer cells, ...
APR 25, 2021
Genetics & Genomics
How Did the Chernobyl Disaster Affect Human Health?
APR 25, 2021
How Did the Chernobyl Disaster Affect Human Health?
It's been about 35 years since the disaster at the Chernobyl nuclear power plant. Now researchers have investigated whet ...
MAY 07, 2021
Cancer
Pandemic times haven't been fun for anyone, but they've been especially hard for cancer patients
MAY 07, 2021
Pandemic times haven't been fun for anyone, but they've been especially hard for cancer patients
The pandemic hit everyone hard on many levels; now, new research from UCSF published in Cancer reports that cancer patie ...
Loading Comments...